VINORELBINE TARTRATE- vinorelbine tartrate injection
Jiangsu Hengrui Medicine Co., Ltd.
----------
WARNING
Vinorelbine Injection USP should be administered under the supervision of a physician experienced in the use of cancer chemotherapeutic agents. This product is for intravenous (IV) use only. Intrathecal administration of other vinca alkaloids has resulted in death. Syringes containing this product should be labeled "WARNING – FOR IV USE ONLY. FATAL if given intrathecally.”
Severe granulocytopenia resulting in increased susceptibility to infection may occur. Granulocyte counts should be ≥1,000 cells/mm3 prior to the administration of Vinorelbine Injection USP. The dosage should be adjusted according to complete blood counts with differentials obtained on the day of treatment.
Caution - It is extremely important that the intravenous needle or catheter be properly positioned before Vinorelbine Injection USP is injected. Administration of Vinorelbine Injection USP may result in extravasation causing local tissue necrosis and/or thrombophlebitis (see DOSAGE AND ADMINISTRATION: Administration Precautions).
Virtual Label - We will be using a PLD to market this product
NDC 57884-3003-1
1 mL Single-Use Vial
VINORELBINE INJECTION
USP, 10mg/mL
Virtual Label - We will be using a PLD to market this product
NDC 57884-3003-1
1 mL Single-Use Vial
VINORELBINE INJECTION
USP, 10mg/mL
VINORELBINE TARTRATE
vinorelbine tartrate injection |
||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
|
Labeler - Jiangsu Hengrui Medicine Co., Ltd. (654147255) |